Tumor-associated antigens for specific immunotherapy of prostate cancer

Cancers

Volumn 4, Issue 1, 2012, Pages 193-217

  Kiessling, Andrea ^a   Wehner, Rebekka ^b   Füssel, Susanne ^b   Bachmann, Michael ^b   Wirth, Manfred P ^b   Schmitz, Marc ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Antibodies; Dendritic cells; Immunotherapy; Prostate cancer; T cells

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CANCER VACCINE; CD3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HLA A ANTIGEN; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY STEAP1; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; PROSTATE STEM CELL ANTIGEN; PROSTATE STEM CELL ANTIGEN ANTIBODY; PROSTEIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SURVIVIN; T CELL RECEPTOR GAMMA ALTERNATE READING FRAME PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; TRP P8 PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL EXPANSION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; METASTASIS POTENTIAL; NONHUMAN; PHAGOCYTE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TARGET CELL; TREATMENT RESPONSE; UNITED STATES;

EID: 84859086934     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010193     Document Type: Review

References (191)

1. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011, The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA. Cancer J. Clin. 2011, 61, 212-236.
2. Heidenreich, A.; Bellmunt, J.; Bolla, M.; Joniau, S.; Mason, M.; Matveev, V.; Mottet, N.; Schmid, H.P.; Van der Kwast, T.; Wiegel, T. et al. EAU guidelines on prostate cancer. Part 1: Screening, Diagnosis, and treatment of clinically localized disease. Europ. Urol. 2011, 59, 61-71.
3. Mottet, N.; Bellmunt, J.; Bolla, M.; Joniau, S.; Mason, M.; Matveev, V.; Schmid, H.P.; Van der Kwast, T.; Wiegel, T.; Zattoni, F.; Heidenreich, A.; EAU guidelines on prostate cancer. Part 2: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Europ. Urol. 2011, 59, 572-583.
4. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I. et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
5. Seruga, B.; Tannock, I.F.; Chemotherapy-based treatment for castration-resistant prostate cancer. J. Clin. Oncol. 2011, 29, 3686-3694.
6. De Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr.; Saad, F. et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic advanced prostate cancer. N. Engl. J. Med. 2011, 364, 1995-2005.
7. Drake, C.G.; Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 2010, 10, 580-593.
8. Cha, E.; Fong, L.; Immunotherapy for prostate cancer. J. Clin. Oncol. 2011, 29, 3677-3685.
9. Rosenberg, S.A.; Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 1997, 18, 175-182.
10. Wang, R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001, 22, 269-276.
11. Dudley, M.E.; Wunderlich, J.R.; Robbins, P.F.; Yang, J.C.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Sherry, R; Restifo, N.P.; Hubicki, A.M. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298, 850-854.
12. Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E.; Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer. 2008, 8, 299-308.
13. Cartellieri, M.; Bachmann, M.; Feldmann, A.; Bippes, C.; Stamova, S.; Wehner, R.; Temme, A.; Schmitz, M.; Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 2010, 956304.
14. Park, T.S, Rosenberg, S.A.; Morgan, R.A.; Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011, 29, 550-557.
15. Morgan, R.A.; Dudley, M.E.; Wunderlich, J.R.; Hughes, M.S.; Yang, J.C.; Sherry, R.M.; Royal, R.E.; Topalian, S.L.; Kammula, U.S.; Restifo, N.P. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314, 126-129.
16. Porter, D.L.; Levine, B.L.; Kalos, M.; Bagg, A.; June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365, 725-733.
17. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18, 767-811.
18. Steinman, R.M.; Banchereau, J. Taking dendritic cells into medicine. Nature 2007, 449, 419-426.
19. Gilboa, E. DC-based cancer vaccines. J. Clin. Invest. 2007, 117, 1195-1203.
20. Palucka, K.; Ueno, H.; Fay, J.; Banchereau, J. Dendritic cells and immunity against cancer. J. Intern. Med. 2011, 269, 64-73.
21. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
22. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
23. Choi, B.D.; Cai, M.; Bigner, D.D.; Mehta, A.I.; Kuan, C.T.; Sampson, J.H. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert. Opin. Biol. Ther. 2011, 11, 843-853.
24. Bargou, R.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321, 974-977.
25. Lundwall, A.; Lilja, H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987, 214, 317-322.
26. Oesterling, J.E. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991, 145, 907-923.
27. Balk, S.P.; Ko, Y.J.; Bubley, G.J. Biology of prostate-specific antigen. J. Clin. Oncol. 2003, 21, 383-391.
28. Freedland, S.J.; Hotaling, J.M.; Fitzsimons, N.J.; Presti, J.C., Jr.; Kane, C.J.; Terris, M.K.; Aronson, W.J.; Amling, C.L. PSA in the new millennium: A powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes-results from the SEARCH database. Eur. Urol. 2008, 53, 758-764.
29. Xue, B.H.; Zhang, Y.; Sosman, J.A.; Peace, D.J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997, 30, 73-78.
30. Correale, P.; Walmsley, K.; Nieroda, C.; Zaremba, S.; Zhu, M.; Schlom, J.; Tsang, K.Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostatespecific antigen. J. Natl. Cancer Inst. 1997, 89, 293-300.
31. Perambakam, S.; Xue, B.H.; Sosman, J.A.; Peace, D.J. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol. Immunother. 2002, 51, 263-270.
32. Terasawa, H.; Tsang, K.Y.; Gulley, J.; Arlen, P.; Schlom, J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. 2002, 8, 41-53.
33. Heiser, A.; Dahm, P.; Yancey, D.R.; Maurice, M.A.; Boczkowski, D.; Nair, S.K.; Gilboa, E.; Vieweg, J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 2000, 164, 5508-5514.
34. Correale, P.; Walmsley, K.; Zaremba, S.; Zhu, M.; Schlom, J.; Tsang, K.Y. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. 1998, 161, 3186-3194.
35. Harada, M.; Kobayashi, K.; Matsueda, S.; Nakagawa, M.; Noguchi, M.; Itoh, K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLAA24+ prostate cancer patients. Prostate 2003, 57, 152-159.
36. Gotoh, M.; Takasu, H.; Harada, K.; Yamaoka, T. Development of HLA-A2402/K(b) transgenic mice. Int. J. Cancer 2002, 100, 565-570.
37. Corman, J.M.; Sercarz, E.E.; Nanda, N.K. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin. Exp. Immunol. 1998, 114, 166-172.
38. Matsueda, S.; Takedatsu, H.; Yao, A.; Tanaka, M.; Noguchi, M.; Itoh, K.; Harada, M. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin. Cancer Res. 2005, 11, 6933-6943.
39. Klyushnenkova, E.N.; Link, J.; Oberle, W.T.; Kodak, J.; Rich, C.; Vandenbark, A.A.; Alexander, R.B.; Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostatespecific antigen. Clin. Cancer Res. 2005, 11, 2853-2861.
40. Mahadevan, M.; Liu, Y.; You, C.; Luo, R.; You, H.; Mehta, J.L.; Hermonat, P.L. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol. Immunother. 2007, 56, 1615-1624.
41. Arredouani, M.S.; Tseng-Rogenski, S.S.; Hollenbeck, B.K.; Escara-Wilke, J.; Leander, K.R.; Defeo-Jones, D.; Hwang, C.; Sanda, M.G. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate 2010, 70, 1002-1011.
42. Drake, C.G.; Doody, A.D.; Mihalyo, M.A.; Huang, C.T.; Kelleher, E.; Ravi, S.; Hipkiss, E.L.; Flies, D.B.; Kennedy, E.P.; Long, M. et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7, 239-249.
43. Murphy, G.P.; Elgamal, A.A.; Su, S.L.; Bostwick, D.G.; Holmes, E.H. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998, 83, 2259-2269.
44. Kawakami, M.; Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997, 57, 2321-2324.
45. Israeli, R.S.; Powell, C.T.; Corr, J.G.; Fair, W.R.; Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54, 1807-1811.
46. Troyer, J.K.; Beckett, M.L.; Wright, G.L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62, 552-558.
47. Sokoloff, R.L.; Norton, K.C.; Gasior, C.L.; Marker, K.M.; Grauer, L.S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000, 43, 150-157.
48. Tjoa, B.; Boynton, A.; Kenny, G.; Ragde, H.; Misrock, S.L.; Murphy, G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996, 28, 65-69.
49. Lu, J.; Celis, E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002, 62, 5807-5812.
50. Harada, M.; Matsueda, S.; Yao, A.; Ogata, R.; Noguchi, M.; Itoh, K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLAA2+ prostate cancer patients. Oncol. Rep. 2004, 12, 601-607.
51. Horiguchi, Y.; Nukaya, I.; Okazawa, K.; Kawashima, I.; Fikes, J.; Sette, A.; Tachibana, M.; Takesako, K.; Murai, M. Screening of HLA-A24-restricted epitope peptides from prostatespecific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 2002, 8, 3885-3892.
52. Kobayashi, K.; Noguchi, M.; Itoh, K.; Harada, M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci. 2003, 94, 622-627.
53. Schroers, R.; Shen, L.; Rollins, L.; Rooney, C.M.; Slawin, K.; Sonderstrup, G.; Huang, X.F.; Chen, S.Y. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003, 9, 4743-4755.
54. Kobayashi, H.; Omiya, R.; Sodey, B.; Yanai, M.; Oikawa, K.; Sato, K.; Kimura, S.; Senju, S.; Nishimura, Y.; Tateno, M.; Celis, E. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin. Cancer Res. 2003, 9, 5386-5393.
55. Kuang, Y.; Weng, X.; Liu, X.; Zhu, H.; Chen, Z.; Jiang, B.; Chen, H. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses. Cancer Lett. 2010, 293, 254-262.
56. McDevitt, M.R.; Barendswaard, E.; Ma, D.; Lai, L.; Curcio, M.J.; Sgouros, G.; Ballangrud, A.M.; Yang, W.H.; Finn, R.D.; Pellegrini, V. et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000, 60, 6095-6100.
57. Fracasso, G.; Bellisola, G.; Cingarlini, S.; Castelletti, D.; Prayer-Galetti, T.; Pagano, F.; Tridente, G.; Colombatti, M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002, 53, 9-23.
58. Vallabhajosula, S.; Smith-Jones, P.M.; Navarro, V.; Goldsmith, S.J.; Bander, N.H. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 2004, 58, 145-155.
59. Smith-Jones, P.M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S.J.; Bander, N.H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 2003, 44, 610-617.
60. Kuroda, K.; Liu, H.; Kim, S.; Guo, M.; Navarro, V.; Bander, N.H. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 2010, 70, 1286-1294.
61. Wolf, P.; Alt, K.; Wetterauer, D.; Buhler, P.; Gierschner, D.; Katzenwadel, A.; Wetterauer, U.; Elsasser-Beile, U. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J. Immunother. 2010, 33, 262-271.
62. Buhler, P.; Wolf, P.; Gierschner, D.; Schaber, I.; Katzenwadel, A.; Schultze-Seemann, W.; Wetterauer, U.; Tacke, M.; Swamy, M.; Schamel, W.W. et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother. 2008, 57, 43-52.
63. Buhler, P.; Molnar, E.; Dopfer, E.P.; Wolf, P.; Gierschner, D.; Wetterauer, U.; Schamel, W.W.; Elsasser-Beile, U. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. J. Immunother. 2009, 32, 565-573.
64. Ma, Q.; Safar, M.; Holmes, E.; Wang, Y.; Boynton, A.L.; Junghans, R.P. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004, 61, 12-25.
65. Solin, T.; Kontturi, M.; Pohlmann, R.; Vihko, P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim. Biophys. Acta. 1990, 1048, 72-77.
66. Cunha, A.C.; Weigle, B.; Kiessling, A.; Bachmann, M.; Rieber, E.P. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006, 236, 229-238.
67. Graddis, T.J.; McMahan, C.J.; Tamman, J.; Page, K.J.; Trager, J.B. Prostatic acid phosphatase expression in human tissues. Int. J. Clin. Exp. Pathol. 2011, 4, 295-306.
68. Goldstein, N.S. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol. 2002, 117, 471-477.
69. Wang, Y.; Harada, M.; Yano, H.; Ogasawara, S.; Takedatsu, H.; Arima, Y.; Matsueda, S.; Yamada, A.; Itoh, K. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J. Immunother. 2005, 28, 535-541.
70. Peshwa, M.V.; Shi, J.D.; Ruegg, C.; Laus, R.; van Schooten, W.C. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998, 36, 129-138.
71. Machlenkin, A.; Paz, A.; Bar, H.E.; Goldberger, O.; Finkel, E.; Tirosh, B.; Volovitz, I.; Vadai, E.; Lugassy, G.; Cytron, S.; Lemonnier, F.; Tzehoval, E.; Eisenbach, L. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res. 2005, 65, 6435-6442.
72. Machlenkin, A.; Azriel-Rosenfeld, R.; Volovitz, I.; Vadai, E.; Lev, A.; Paz, A.; Goldberger, O.; Reiter, Y.; Tzehoval, E.; Benhar, I.; Eisenbach, L. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol. Immunother. 2007, 56, 217-226.
73. Olson, B.M.; Frye, T.P.; Johnson, L.E.; Fong, L.; Knutson, K.L.; Disis, M.L.; McNeel, D.G. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol. Immunother. 2010, 59, 943-953.
74. Inoue, Y.; Takaue, Y.; Takei, M.; Kato, K.; Kanai, S.; Harada, Y.; Tobisu, K.; Noguchi, M.; Kakizoe, T.; Itoh, K.; Wakasugi, H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J. Urol. 2001, 166, 1508-1513.
75. Terasaki, Y.; Shichijo, S.; Niu, Y.; Komatsu, N.; Noguchi, M.; Todo, S.; Itoh, K. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol. Immunother. 2009, 58, 1877-1885.
76. Klyushnenkova, E.N.; Kouiavskaia, D.V.; Kodak, J.A.; Vandenbark, A.A.; Alexander, R.B. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 2007, 67, 1019-1028.
77. Klyushnenkova, E.N.; Alexander, R.B. CD4 T-Cell-mediated immune response to prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel HLA-DRB1*1503- restricted T-cell epitope from human prostatic acid phosphatase. Prostate 2011, 71, 561-566.
78. Spies, E.; Reichardt, W.; Alvarez, G.; Groettrup, M.; Ohlschlager, P. An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma. Mol. Ther. 2011, [Epub ahead of print].
79. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B. et al. Sipuleucel-T immunotherapy for castrationresistent prostate cancer. N. Engl. J. Med. 2010, 363, 411-422.
80. Reiter, R.E.; Gu, Z.; Watabe, T.; Thomas, G.; Szigeti, K.; Davis, E.; Wahl, M.; Nisitani, S.; Yamashiro, J.; Le Beau, M.M.; Loda, M.; Witte, O.N. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 1998, 95, 1735-1740.
81. Gu, Z.; Thomas, G.; Yamashiro, J.; Shintaku, I.P.; Dorey, F.; Raitano, A.; Witte, O.N.; Said, J.W.; Loda, M.; Reiter, R.E. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19, 1288-1296.
82. Joung, J.Y.; Yang, S.O.; Jeong, I.G.; Han, K.S.; Seo, H.K.; Chung, J.; Park, W.S.; Lee, K.H. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: Potential value in molecular staging of prostate cancer. Int. J. Urol. 2007, 14, 635-643.
83. Lam, J.S.; Yamashiro, J.; Shintaku, I.P.; Vessella, R.L.; Jenkins, R.B.; Horvath, S.; Said, J.W.; Reiter, R.E. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 2005, 11, 2591-2596.
84. Raff, A.B.; Gray, A.; Kast, W.M. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett. 2009, 277, 126-132.
85. Dannull, J.; Diener, P.A.; Prikler, L.; Furstenberger, G.; Cerny, T.; Schmid, U.; Ackermann, D.K.; Groettrup, M. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000, 60, 5522-5528.
86. Kiessling, A.; Schmitz, M.; Stevanovic, S.; Weigle, B.; Holig, K.; Fussel, M.; Fussel, S.; Meye, A.; Wirth, M.P.; Rieber, E.P. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int. J. Cancer 2002, 102, 390-397.
87. Matsueda, S.; Kobayashi, K.; Nonaka, Y.; Noguchi, M.; Itoh, K.; Harada, M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol. Immunother. 2004, 53, 479-489.
88. Matsueda, S.; Yao, A.; Ishihara, Y.; Ogata, R.; Noguchi, M.; Itoh, K.; Harada, M. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients. Prostate 2004, 60, 205-213.
89. Garcia-Hernandez, M.L.; Gray, A.; Hubby, B.; Klinger, O.J.; Kast, W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68, 861-869.
90. Krupa, M.; Canamero, M.; Gomez, C.E.; Najera, J.L.; Gil, J.; Esteban, M. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 2011, 29, 1504-1513.
91. Ross, S.; Spencer, S.D.; Holcomb, I.; Tan, C.; Hongo, J.; Devaux, B.; Rangell, L.; Keller, G.A.; Schow, P.; Steeves, R.M. et al. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002, 62, 2546-2553.
92. Saffran, D.C.; Raitano, A.B.; Hubert, R.S.; Witte, O.N.; Reiter, R.E.; Jakobovits, A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. USA 2001, 98, 2658-2663.
93. Gu, Z.; Yamashiro, J.; Kono, E.; Reiter, R.E. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005, 65, 9495-9500.
94. Olafsen, T.; Gu, Z.; Sherman, M.A.; Leyton, J.V.; Witkosky, M.E.; Shively, J.E.; Raubitschek, A.A.; Morrison, S.L.; Wu, A.M.; Reiter, R.E. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 2007, 30, 396-405.
95. Olafsen, T.; Sherman, M.A.; Leyton, J.V.; Witkosky, M.E.; Shively, J.E.; Raubitschek, A.A.; Morrison, S.L.; Wu, A.M.; Reiter, R.E. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 2007, 30, 396-405.
96. Feldmann, A.; Stamova, S.; Bippes, C.C.; Bartsch, H.; Wehner, R.; Schmitz, M.; Temme, A.; Cartellieri, M.; Bachmann, M. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats. Prostate 2011, 71, 998-1011.
97. Morgenroth, A.; Cartellieri, M.; Schmitz, M.; Gunes, S.; Weigle, B.; Bachmann, M.; Abken, H.; Rieber, E.P.; Temme, A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007, 67, 1121-1131.
98. Xu, J.; Kalos, M.; Stolk, J.A.; Zasloff, E.J.; Zhang, X.; Houghton, R.L.; Filho, A.M.; Nolasco, M.; Badaro, R.; Reed, S.G. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res. 2001, 61, 1563-1568.
99. Kalos, M.; Askaa, J.; Hylander, B.L.; Repasky, E.A.; Cai, F.; Vedvick, T.; Reed, S.G.; Wright, G.L., Jr.; Fanger, G.R. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate 2004, 60, 246-256.
100. Musiyenko, A.; Bitko, V.; Barik, S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. 2008, 86, 313-322.
101. Kiessling, A.; Stevanovic, S.; Fussel, S.; Weigle, B.; Rieger, M.A.; Temme, A.; Rieber, E.P.; Schmitz, M. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. Br. J. Cancer 2004, 90, 1034-1040.
102. Schmidt, U.; Fuessel, S.; Koch, R.; Baretton, G.B.; Lohse, A.; Tomasetti, S.; Unversucht, S.; Froehner, M.; Wirth, M.P.; Meye, A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006, 66, 1521-1534.
103. Friedman, R.S.; Spies, A.G.; Kalos, M. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur. J. Immunol. 2004, 34, 1091-1101.
104. Wolfgang, C.D.; Essand, M.; Vincent, J.J.; Lee, B.; Pastan, I. TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc. Natl. Acad. Sci. USA 2000, 97, 9437-9442.
105. Cheng, W.S.; Giandomenico, V.; Pastan, I.; Essand, M. Characterization of the androgen- regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology 2003, 144, 3433-3440.
106. Maeda, H.; Nagata, S.; Wolfgang, C.D.; Bratthauer, G.L.; Bera, T.K.; Pastan, I. The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria. J. Biol. Chem. 2004, 279, 24561-24568.
107. Carlsson, B.; Totterman, T.H.; Essand, M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 2004, 61, 161-170.
108. Oh, S.; Terabe, M.; Pendleton, C.D.; Bhattacharyya, A.; Bera, T.K.; Epel, M.; Reiter, Y.; Phillips, J.; Linehan, W.M.; Kasten-Sportes, C. et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 2004, 64, 2610-2618.
109. Kobayashi, H.; Nagato, T.; Oikawa, K.; Sato, K.; Kimura, S.; Aoki, N.; Omiya, R.; Tateno, M.; Celis, E. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin. Cancer Res. 2005, 11, 3869-3878.
110. Epel, M.; Carmi, I.; Soueid-Baumgarten, S.; Oh, S.K.; Bera, T.; Pastan, I.; Berzofsky, J.; Reiter, Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur. J. Immunol. 2008, 38, 1706-1720.
111. Tsavaler, L.; Shapero, M.H.; Morkowski, S.; Laus, R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001, 61, 3760-3769.
112. Kiessling, A.; Fussel, S.; Schmitz, M.; Stevanovic, S.; Meye, A.; Weigle, B.; Klenk, U.; Wirth, M.P.; Rieber, E.P. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate 2003, 56, 270-279.
113. Hubert, R.S.; Vivanco, I.; Chen, E.; Rastegar, S.; Leong, K.; Mitchell, S.C.; Madraswala, R.; Zhou, Y.; Kuo, J.; Raitano, A.B. et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA 1999, 96, 14523-14528.
114. Challita-Eid, P.M.; Morrison, K.; Etessami, S.; An, Z.; Morrison, K.J.; Perez-Villar, J.J.; Raitano, A.B.; Jia, X.C.; Gudas, J.M.; Kanner, S.B.; Jakobovits, A. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 2007, 67, 5798-5805.
115. Rodeberg, D.A.; Nuss, R.A.; Elsawa, S.F.; Celis, E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin. Cancer Res. 2005, 11, 4545-4552.
116. Alves, P.M.; Faure, O.; Graff-Dubois, S.; Cornet, S.; Bolonakis, I.; Gross, D.A.; Miconnet, I.; Chouaib, S.; Fizazi, K.; Soria, J.C.; Lemonnier, F.A.; Kosmatopoulos, K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol. Immunother. 2006, 55, 1515-1523.
117. Kobayashi, H.; Nagato, T.; Sato, K.; Aoki, N.; Kimura, S.; Murakami, M.; Iizuka, H.; Azumi, M.; Kakizaki, H.; Tateno, M.; Celis, E. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res. 2007, 67, 5498-5504.
118. Azumi, M.; Kobayashi, H.; Aoki, N.; Sato, K.; Kimura, S.; Kakizaki, H.; Tateno, M. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J. Urol. 2010, 183, 2036-2044.
119. Hayashi, S.; Kumai, T.; Matsuda, Y.; Aoki, N.; Sato, K.; Kimura, S.; Kitada, M.; Tateno, M.; Celis, E.; Kobayashi, H. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J. Transl. Med. 2011, 9, 191.
120. Garcia-Hernandez, M.L.; Gray, A.; Hubby, B.; Kast, W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: A candidate antigen for treating prostate cancer. Cancer Res. 2007, 67, 1344-1351.
121. Kim, S.; Lee, J.B.; Lee, G.K.; Chang, J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009, 69, 938-948.
122. Guise, T.A. Parathyroid hormone-related protein and bone metastases. Cancer 1997, 80, 1572-1580.
123. Arima, Y.; Matsueda, S.; Yano, H.; Harada, M.; Itoh, K. Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types. Int. J. Oncol. 2005, 27, 981-988.
124. Francini, G.; Scardino, A.; Kosmatopoulos, K.; Lemonnier, F.A.; Campoccia, G.; Sabatino, M.; Pozzessere, D.; Petrioli, R.; Lozzi, L.; Neri, P. et al. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 2002, 169, 4840-4849.
125. Yao, A.; Harada, M.; Matsueda, S.; Ishihara, Y.; Shomura, H.; Takao, Y.; Noguchi, M.; Matsuoka, K.; Hara, I.; Kamidono, S.; Itoh, K. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Prostate 2005, 62, 233-242.
126. Yao, A.; Harada, M.; Matsueda, S.; Ishihara, Y.; Shomura, H.; Noguchi, M.; Matsuoka, K.; Hara, I.; Kamidono, S.; Itoh, K. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. Br. J. Cancer 2004, 91, 287-296.
127. Yamada, T.; Muguruma, H.; Yano, S.; Ikuta, K.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Uehara, H.; Nishioka, Y.; Sone, S. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. Mol. Cancer Ther. 2009, 8, 119-126.
128. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Coviello, G.M.; Wright, W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266, 2011-2015.
129. Vonderheide, R.H.; Hahn, W.C.; Schultze, J.L.; Nadler, L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10, 673-679.
130. Minev, B.; Hipp, J.; Firat, H.; Schmidt, J.D.; Langlade-Demoyen, P.; Zanetti, M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 2000, 97, 4796-4801.
131. Hernandez, J.; Garcia-Pons, F.; Lone, Y.C.; Firat, H.; Schmidt, J.D.; Langlade-Demoyen, P.; Zanetti, M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. USA 2002, 99, 12275-12280.
132. Thorn, M.; Wang, M.; Kloverpris, H.; Schmidt, E.G.; Fomsgaard, A.; Wenandy, L.; Berntsen, A.; Brunak, S.; Buus, S.; Claesson, M.H. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunol. Immunother. 2007, 56, 1755-1763.
133. Schreurs, M.W.; Kueter, E.W.; Scholten, K.B.; Kramer, D.; Meijer, C.J.; Hooijberg, E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol. Immunother. 2005, 54, 703-712.
134. Vonderheide, R.H.; Anderson, K.S.; Hahn, W.C.; Butler, M.O.; Schultze, J.L.; Nadler, L.M. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 2001, 7, 3343-3348.
135. Arai, J.; Yasukawa, M.; Ohminami, H.; Kakimoto, M.; Hasegawa, A.; Fujita, S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001, 97, 2903-2907.
136. Mizukoshi, E.; Nakamoto, Y.; Marukawa, Y.; Arai, K.; Yamashita, T.; Tsuji, H.; Kuzushima, K.; Takiguchi, M.; Kaneko, S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006, 43, 1284-1294.
137. Adotevi, O.; Mollier, K.; Neuveut, C.; Cardinaud, S.; Boulanger, E.; Mignen, B.; Fridman, W.H.; Zanetti, M.; Charneau, P.; Tartour, E.; Lemonnier, F.; Langlade-Demoyen, P. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin. Cancer Res. 2006, 12, 3158-3167.
138. Schroers, R.; Huang, X.F.; Hammer, J.; Zhang, J.; Chen, S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002, 62, 2600-2605.
139. Schroers, R.; Shen, L.; Rollins, L.; Rooney, C.M.; Slawin, K.; Sonderstrup, G.; Huang, X.F.; Chen, S.Y. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer. Res. 2003, 9, 4743-4755.
140. Fukuda, S.; Pelus, L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5, 1087-1098.
141. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921.
142. Ryan, B.M.; O'Donovan, N.; Duffy, M.J. Survivin: A new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35, 553-562.
143. Zhang, M.; Latham, D.E.; Delaney, M.A.; Chakravarti, A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24, 2474-2482.
144. Schmitz, M.; Diestelkoetter, P.; Weigle, B.; Schmachtenberg, F.; Stevanovic, S.; Ockert, D.; Rammensee, H.G.; Rieber, E.P. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000, 60, 4845-4849.
145. Siegel, S.; Steinmann, J.; Schmitz, N.; Stuhlmann, R.; Dreger, P.; Zeis, M. Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia 2004, 18, 2046-2047.
146. Andersen, M.H.; Pedersen, L.O.; Becker, J.C.; Straten, P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001, 61, 869-872.
147. Reker, S.; Becker, J.C.; Svane, I.M.; Ralfkiaer, E.; Straten, P.T.; Andersen, M.H. HLA-B35-restricted immune responses against survivin in cancer patients. Int. J. Cancer 2004, 108, 937-941.
148. Reker, S.; Meier, A.; Holten-Andersen, L.; Svane, I.M.; Becker, J.C.; thor Straten, P.; Andersen, M.H.; Identification of novel survivin-derived CTL epitopes. Cancer Biol. Ther. 2004, 3, 173-179.
149. Hirohashi, Y.; Torigoe, T.; Maeda, A.; Nabeta, Y.; Kamiguchi, K.; Sato, T.; Yoda, J.; Ikeda, H.; Hirata, K.; Yamanaka, N.; Sato, N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. 2002, 8, 1731-1739.
150. Piesche, M.; Hildebrandt, Y.; Zettl, F.; Chapuy, B.; Schmitz, M.; Wulf, G.; Trumper, L.; Schroers, R. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum. Immunol. 2007, 68, 572-576.
151. Wang, X.F.; Kerzerho, J.; Adotevi, O.; Nuyttens, H.; Badoual, C.; Munier, G.; Oudard, S.; Tu, S.; Tartour, E.; Maillere, B. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 2008, 181, 431-439.
152. Xiang, R.; Mizutani, N.; Luo, Y.; Chiodoni, C.; Zhou, H.; Mizutani, M.; Ba, Y.; Becker, J.C.; Reisfeld, R.A. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65, 553-561.
153. Ciesielski, M.J.; Kozbor, D.; Castanaro, C.A.; Barone, T.A.; Fenstermaker, R.A. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol. Immunother. 2008, 57, 1827-1835.
154. Hernes, E.; Fossa, S.D.; Berner, A.; Otnes, B.; Nesland, J.M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br. J. Cancer 2004, 90, 449-454.
155. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T. et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010, 376, 687-697.
156. Di Lorenzo, G.; Autorino, R.; De Laurentiis, M.; Cindolo, L.; D'Armiento, M.; Bianco, A.R.; De Placidos, S. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004, 90, 163-170.
157. Neto, A.S.; Tobias-Machado, M.; Wroclawski, M.L.; Fonseca, F.L.; Teixeira, G.K.; Amarante, R.D.; Wroclawski, E.R.; Del, G.A. Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J. Urol. 2010, 184, 842-850.
158. Baxevanis, C.N.; Voutsas, I.F.; Gritzapis, A.D.; Perez, S.A.; Papamichail, M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010, 2, 213-226.
159. Agus, D.B.; Scher, H.I.; Higgins, B.; Fox, W.D.; Heller, G.; Fazzari, M.; Cordon-Cardo, C.; Golde, D.W. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res. 1999, 59, 4761-4764.
160. Formento, P.; Hannoun-Levi, J.M.; Gerard, F.; Mazeau, C.; Fischel, J.L.; Etienne-Grimaldi, M.C.; Gugenheim, J.; Milano, G. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur. J. Cancer 2005, 41, 1467-1473.
161. Pinthus, J.H.; Waks, T.; Malina, V.; Kaufman-Francis, K.; Harmelin, A.; Aizenberg, I.; Kanety, H.; Ramon, J.; Eshhar, Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 2004, 114, 1774-1781.
162. Di Lorenzo, G.; Tortora, G.; D'Armiento, F.P.; De Rosa,G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De, Placidos, S.; Catalano, G. et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen- independence in human prostate cancer. Clin. Cancer Res. 2002, 8, 3438-3444.
163. de Muga, S.; Hernandez, S.; Agell, L.; Salido, M.; Juanpere, N.; Lorenzo, M.; Lorente, J.A.; Serrano, S.; Lloreta, J. Molecular alterations of EGFR and PTEN in prostate cancer: Association with high-grade and advanced-stage carcinomas. Mod. Pathol. 2010, 23, 703-712.
164. Yang, X.D.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G.; Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999, 59, 1236-1243.
165. Prewett, M.; Rockwell, P.; Rockwell, R.F.; Giorgio, N.A.; Mendelsohn, J.; Scher, H.I.; Goldstein, N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis. Tumor Immunol. 1996, 19, 419-427.
166. Shomura, H.; Shichijo, S.; Komatsu, N.; Matsueda, S.; Mine, T.; Rikimaru, T.; Sato, Y.; Todo, S.; Itoh, K. Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. Eur. J. Cancer 2004, 40, 1776-1786.
167. Andrade Filho, P.A.; López-Albaitero, A.; Gooding, W.; Ferris, R.L. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J. Immunother. 2010, 33, 83-91.
168. Wheeler, D.L.; Rangnekar, V.M.; Schwarze, S.R. ErbB4 targeting approaches for prostate cancer treatment. Cancer Biol. Ther. 2008, 7, 1095-1097.
169. Ben-Yosef, R.; Starr, A.; Karaush, V.; Loew, V.; Lev-Ari, S.; Barnea, I.; Lidawi, G.; Shtabsky, A.; Greif, Y.; Yarden, Y. et al. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 2007, 67, 871-880.
170. Vexler, A.; Lidawi, G.; Loew, V.; Barnea, I.; Karaush, V.; Lev-Ari, S.; Shtabsky, A.; Ben-Yosef, R. Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies. Cancer Biol. Ther. 2008, 7, 1090-1094.
171. Maeda, M.; Johnson, K.R.; Wheelock, M.J. Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J. Cell Sci. 2005, 118, 873-887.
172. Gravdal, K.; Halvorsen, O.J.; Haukaas, S.A.; Akslen, L.A. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 2007, 13, 7003-7011.
173. Jaggi, M.; Nazemi, T.; Abrahams, N.A.; Baker, J.J.; Galich, A.; Smith, L.M.; Balaji, K.C. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 2006, 66, 193-199.
174. Jennbacken, K.; Tesan, T.; Wang, W.; Gustavsson, H.; Damber, J.E.; Welen, K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 2010, 17, 469-479.
175. Tanaka, H.; Kono, E.; Tran, C.P.; Miyazaki, H.; Yamashiro, J.; Shimomura, T.; Fazli, L.; Wada, R.; Huang, J.; Vessella, R.L. et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 2010, 16, 1414-1420.
176. Hafner, C.; Becker, B.; Landthaler, M.; Vogt, T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod. Pathol. 2006, 19, 1369-1377.
177. Tandon, M.; Vemula, S.V.; Mittal, S.K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert. Opin. Ther. Targets 2011, 15, 31-51.
178. Tatsumi, T.; Herrem, C.J.; Olson, W.C.; Finke, J.H.; Bukowski, R.M.; Kinch, M.S.; Ranieri, E.; Storkus, W.J. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003, 63, 4481-4489.
179. Alves, P.M.; Faure, O.; Graff-Dubois, S.; Gross, D.A.; Cornet, S.; Chouaib, S.; Miconnet, I.; Lemonnier, F.A.; Kosmatopoulos, K. EphA2 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Cancer Res. 2003, 63, 8476-8480.
180. Hatano, M.; Kuwashima, N.; Tatsumi, T.; Dusak, J.E.; Nishimura, F.; Reilly, K.M.; Storkus, W.J.; Okada, H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J. Transl. Med. 2004, 2, 40.
181. Yamaguchi, S.; Tatsumi, T.; Takehara, T.; Sakamori, R.; Uemura, A.; Mizushima, T.; Ohkawa, K.; Storkus, W.J.; Hayashi, N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110, 1469-1477.
182. Landen, C.N., Jr.; Lu, C.; Han, L.Y.; Coffman, K.T.; Bruckheimer, E.; Halder, J.; Mangala, L.S.; Merritt, W.M.; Lin, Y.G.; Gao, C. et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst. 2006, 98, 1558-1570.
183. Peng, L.; Oganesyan, V.; Damschroder, M.M.; Wu, H.; Dall'Acqua, W.F. Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J. Mol. Biol. 2011, 413, 390-405.
184. Bruckheimer, E.M.; Fazenbaker, C.A.; Gallagher, S.; Mulgrew, K.; Fuhrmann, S.; Coffman, K.T.; Walsh, W.; Ready, S.; Cook, K.; Damschroder, M. et al. Antibody-dependent cellmediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 2009, 11, 509-517.
185. Jackson, D.; Gooya, J.; Mao, S.; Kinneer, K.; Xu, L.; Camara, M.; Fazenbaker, C.; Fleming, R.; Swamynathan, S.; Meyer, D. et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008, 68, 9367-9374.
186. Lee, J.W.; Han, H.D.; Shahzad, M.M.; Kim, S.W.; Mangala, L.S.; Nick, A.M.; Lu, C.; Langley, R.R.; Schmandt, R.; Kim, H.S. et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2009, 101, 1193-1205.
187. Lee, J.W.; Stone, R.L.; Lee, S.J.; Nam, E.J.; Roh, J.W.; Nick, A.M.; Han, H.D.; Shahzad, M.M.; Kim, H.S.; Mangala, L.S. et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res. 2010, 16, 2562-2570.
188. Smith, H.A.; McNeel, D.G. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin. Dev. Immunol. 2010, 2010, 150591.
189. Gure, A.O.; Tureci, O.; Sahin, U.; Tsang, S.; Scanlan, M.J.; Jager, E.; Knuth, A.; Pfreundschuh, M.; Old, L.J.; Chen, Y.T. SSX: A multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 1997, 72, 965-971.
190. Smith, H.A.; Cronk, R.J.; Lang, J.M.; McNeel, D.G. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 2011, 71, 6785-6795.
191. Smith, H.A.; McNeel, D.G. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J. Immunother. 2011, 34, 569-580.